In particular, the TKI sorafenib is an oral multi-kinase inhibitor that mainly targets the VEGF and PDGF pathways, thereby suppressing tumor proliferation and angiogenesis,[18] and shows potent anti-tumor activity in patients with metastatic RCC.[19,20] Furthermore, sorafenib also showed a significantly greater therapeutic effect for RCC patients compared with interferon treatment.[21]. This evidence concerns the gene VEGFA and neoplasm.